The Filing Desk

Immunome vs Ovid Therapeutics

Immunome IMNM · Ovid Therapeutics OVID · Pharmaceuticals

Ovid Therapeutics reported revenue of $7 million in fiscal 2025, about the same as Immunome's $7 million in fiscal 2025. Immunome's revenue fell 23.2% in its latest year, and Ovid Therapeutics' grew 1181.3%. Immunome had an operating margin of -3228.8%, against -585.2% at Ovid Therapeutics. Free cash flow was −$201 million at Immunome and −$38 million at Ovid Therapeutics.

Side by side

ImmunomeOvid Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$7M$7M
Revenue growth−23.2%1,181.3%
Revenue growth a year, last 5 years—−10.3%
Gross margin——
Operating margin−3,228.8%−585.2%
Net margin−3,060.0%−240.1%
Free cash flow−$201M−$38M
Free cash flow margin−2,890.1%−528.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count49.0%—
Last close$18.77$2.54
P/E at the last close——
Insider trades, last 12 monthsbought $2.3 million, sold $27.5 million—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ImmunomeOvid Therapeutics
Operating margin
Percent of revenue
ImmunomeOvid Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ImmunomeOvid Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Immunome and Ovid Therapeutics pages.